Abstract
Cancer cells tend to obtain the substances needed for their development depending on altering metabolic characteristics. Among the reorganized metabolic pathways, Glutamine pathway, reprogrammed to be involved in the physiological process including energy supply, biosynthesis and redox homeostasis, occupies an irreplaceable role in tumor cells and has become a hot topic in recent years. Lung cancer currently maintains a high morbidity and mortality rate among all types of tumors and has been a health challenge that researchers have longed to overcome. Therefore, this study aimed to clarify the essential role of glutamine pathway played in the metabolism of lung cancer and its potential therapeutic value in the interventions of lung cancer.
Highlights
For nearly a century, tumors have been found to display metabolic activities that distinguish them from well-differentiated, non-proliferative tissues, which may contribute to their physiological survival and growth [1]
HIF-1a-mediated downregulation of NUDT21 under hypoxic conditions altered the expression patterns of both isoforms of GLS, glutaminase C (GAC) and KGA. These results link the tumor hypoxic environment to aberrant Gln metabolism, which is important for the cellular energy supply of small cell lung cancer (SCLC) cells; NUDT21 can be considered as a potential target for SCLC therapy [50]
Metabolic reprograming occupies an irreplaceable role in tumor cells and has become a hot topic in recent years for researchers attempting to develop new tumor interventions
Summary
Enyu Tang †, Siyang Liu †, Zhiming Zhang , Rixin Zhang , Dejing Huang , Tong Gao , Tianze Zhang and Guangquan Xu*. Edited by: Ashleigh Poh, Olivia Newton-John Cancer Research Institute, Australia. Reviewed by: Yu-Chan Chang, National Yang-Ming University, Taiwan Deanna Edwards, Vanderbilt University Medical Center, United States. Specialty section: This article was submitted to Thoracic Oncology, a section of the journal
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
